StonvexLoading…
StonvexStonvexStonvexCore line items from CSL's most recent SEC filings (10-K / 10-Q via EDGAR XBRL). Last 4 reporting periods.
| Metric | Q1 2026 2026-03-31 | Annual 2025 2025-12-31 | Q3 2025 2025-09-30 | Q2 2025 2025-06-30 |
|---|---|---|---|---|
Revenue | $1.05B | $5.02B | $3.89B | $2.55B |
Operating Income | $180.30M | $1.00B | $812.50M | $518.60M |
Net Income | $127.70M | $740.70M | $613.30M | $399.10M |
EPS (Diluted) | $3.10 | $17.12 | $14.03 | $9.05 |
Total Assets | $5.99B | $6.26B | $6.46B | $5.52B |
Total Liabilities | Not available | Not available | Not available | Not available |
Cash & Equivalents | $771.30M | $1.11B | $1.10B | $68.40M |
Free Cash Flow OCF − CapEx | $-73.00M | $970.60M | $624.50M | $231.10M |
Shares Outstanding | 40.50M | 41.00M | 41.90M | 42.60M |